Department of Biostatistics and Epidemiology, University of Massachusetts Amherst, Amherst, Massachusetts.
Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Cancer Epidemiol Biomarkers Prev. 2018 Mar;27(3):306-314. doi: 10.1158/1055-9965.EPI-17-0707. Epub 2017 Dec 20.
Depression and antidepressant use is highly prevalent among U.S. women and may be related to increased breast cancer risk. However, prior studies are not in agreement regarding an increase in risk. We conducted a prospective cohort study within the Nurses' Health Study (NHS) and NHSII among females age 25 and older. Over more than 10 years of follow-up in each cohort, 4,014 incident invasive breast cancers were diagnosed. We used Cox proportional hazards regressions with updating of exposures and covariates throughout follow-up to estimate HRs and 95% confidence intervals (CIs) for associations between clinical depression and antidepressant use with invasive breast cancer risk. Analyses were repeated separately for disease, as well as stratified by estrogen receptor (ER) subtype and menopausal status at diagnosis. No statistically significant associations were observed between clinical depression (HR for reporting ≥3 times vs. 0, 1.13; 95% CI, 0.85-1.49) or antidepressant use (HR for reporting ≥3 times vs. 0, 0.92; 95% CI, 0.80-1.05) and invasive breast cancer risk in multivariable analyses. Likewise, we observed no significant associations between clinical depression or antidepressant use and risk of , ER, ER, premenopausal, or postmenopausal breast cancer. In the largest prospective study to date, we find no evidence that either depression or antidepressant use increase risk of breast cancer. The results of this study are reassuring in that neither depression nor antidepressant use appear to be related to subsequent breast cancer risk. .
在美国女性中,抑郁和抗抑郁药的使用非常普遍,并且可能与乳腺癌风险增加有关。然而,之前的研究对于风险增加并没有达成一致意见。我们在 25 岁及以上的女性中进行了一项前瞻性队列研究,该研究是护士健康研究(NHS)和 NHSII 中的一部分。在每个队列的 10 多年随访中,诊断出了 4014 例浸润性乳腺癌。我们使用了 Cox 比例风险回归,在整个随访过程中更新了暴露和协变量,以估计临床抑郁和抗抑郁药使用与浸润性乳腺癌风险之间的 HRs 和 95%置信区间(CIs)。我们分别对所有浸润性乳腺癌、以及根据诊断时的雌激素受体(ER)亚型和绝经状态进行了分层分析。在多变量分析中,我们没有观察到临床抑郁(报告≥3 次与报告 0 次相比的 HR,1.13;95%CI,0.85-1.49)或抗抑郁药使用(报告≥3 次与报告 0 次相比的 HR,0.92;95%CI,0.80-1.05)与浸润性乳腺癌风险之间存在统计学显著关联。同样,我们也没有观察到临床抑郁或抗抑郁药使用与浸润性乳腺癌、ER-、ER+、绝经前或绝经后乳腺癌风险之间存在显著关联。在迄今为止最大的前瞻性研究中,我们没有发现证据表明抑郁或抗抑郁药的使用会增加乳腺癌的风险。这项研究的结果令人安心,因为抑郁或抗抑郁药的使用似乎都与随后的乳腺癌风险无关。